Desroxia Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Deferasirox

Indications/Uses

Chronic Fe overload due to frequent blood transfusions (≥7 mL/kg/mth of packed RBC) in patients w/ β thalassaemia major aged ≥6 yr; when deferoxamine therapy is contraindicated or inadequate in patients w/ other anaemias, aged 2-5 yr, w/ β thalassaemia major w/ Fe overload due to infrequent blood transfusions (<7 mL/kg/mth of packed RBC). Chronic Fe overload in patients w/ non-transfusion-dependent thalassemia syndromes aged ≥10 yr.

Dosage/Direction for Use

Transfusional Fe overload Starting dose: 14 mg/kg. Patient receiving >14 mL/kg/mth of packed RBC (approx >4 u/mth for an adult) & for whom the objective is Fe overload reduction Consider initial daily dose of 21 mg/kg. Patient receiving <7 mL/kg/mth of packed RBC (approx <2 u/mth for an adult) & for whom the objective is maintenance of body Fe level Consider initial daily dose of 7 mg/kg. Non-transfusion-dependent thalassemia (NTDT) syndromes Starting dose: 7 mg/kg. Transfusional Fe overload & NTDT syndromes Patient already well-managed w/ deferoxamine 60 mg/kg 21 mg/kg daily, 50 mg/kg 17.5 mg/kg daily, 40 mg/kg 14 mg/kg daily, 30 mg/kg 10.5 mg/kg daily, 20 mg/kg 7 mg/kg daily, 10 mg/kg 3.5 mg/kg daily. Moderate hepatic impairment (Child-Pugh B) Reduce starting dose by approx 50%.

Administration

May be taken with or without food: Take at the same time each day. Swallow whole. May be crushed & administered by sprinkling the full dose on soft food eg, yogurt or apple sauce (apple puree).

Contraindications

Hypersensitivity. High-risk myelodysplastic syndrome patients & those w/ other hematological & non-hematological malignancies who are not expected to benefit from chelation therapy due to the rapid progression of their disease. CrCl <60 mL/min or serum creatinine >2x ULN.

MIMS Class

Antidotes & Detoxifying Agents

ATC Classification

V03AC03 - deferasirox ; Belongs to the class of iron chelating agents. Used in the management of chronic iron overload associated with blood transfusion.

Regulatory Classification

POM

Presentation/Packing

Form

Desroxia FC tab 360 mg

Packing/Price

1's

Form

Desroxia FC tab 90 mg

Packing/Price

1's

Desroxia

deferasirox

Manufacturer:

PharOS MT Ltd